Feasibility, efficacy and toxicity of carboplatin and paclitaxel as a first-line treatment in elderly patients with ovarian cancer

被引：1
|
作者：
Kotani, N. [1 ]
Katsumata, N. [1 ]
Yonemori, K. [1 ]
Hirakawa, A. [2 ]
Yamamoto, H. [1 ]
Ono, M. [1 ]
Hirata, T. [1 ]
Yunokawa, M. [1 ]
Kouno, T. [1 ]
Shimizu, C. [1 ]
Tamura, K. [1 ]
Fujiwara, Y. [1 ]
机构：
[1] Natl Canc Ctr, Breast & Med Oncol Div, Tokyo, Japan
[2] Tokyo Univ Sci, Grad Sch Engn, Dept Management Sci, Tokyo 162, Japan
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2009年 / 72卷
关键词：
D O I：
10.1016/S1040-8428(09)70099-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: Feasibility and toxicity
    Meden, H
    Wittkop, Y
    Kuhn, W
    ANTICANCER RESEARCH, 1997, 17 (3C) : 2221 - 2223
  • [32] Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer
    Ngoi, Natalie Y. L.
    Syn, Nicholas L. X.
    Goh, Robby M.
    Goh, Boon Cher
    Huang, Ruby Yun-Ju
    Soon, Yu Yang
    James, Elizabeth
    Cook, Adrian
    Clamp, Andrew
    Tan, David S. P.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (02):
  • [33] Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer
    Friedlander, M.
    Buck, M.
    Wyld, D.
    Findlay, M.
    Fitzharris, B.
    De Souza, P.
    Davies, T.
    Kalimi, G.
    Allan, S.
    Perez, D.
    Harnett, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) : 350 - 358
  • [34] Surgical reassessment results of a phase II study of erlotinib, carboplatin, and paclitaxel as first-line treatment of ovarian cancer
    Blank, Stephanie V.
    Curtin, John P.
    Goldman, Noah
    Runowicz, Carolyn D.
    Wadler, Scott
    Muggia, Franco M.
    GYNECOLOGIC ONCOLOGY, 2007, 104 (03) : S17 - S17
  • [35] Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer
    du Bois, Andreas
    Herrstedt, Jorn
    Hardy-Bessard, Anne-Claire
    Mueller, Hans-Helge
    Harter, Philipp
    Kristensen, Gunnar
    Joly, Florence
    Huober, Jens
    Avall-Lundqvist, Elisabeth
    Weber, Beatrice
    Kurzeder, Christian
    Jelic, Svetislav
    Pujade-Lauraine, Eric
    Burges, Alexander
    Pfisterer, Jacobus
    Gropp, Martina
    Staehle, Anne
    Wimberger, Pauline
    Jackisch, Christian
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4162 - 4169
  • [36] Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: Preliminary results of a phase I study
    Lhomme, C
    Kerbrat, P
    Lejeune, C
    Guastalla, JP
    Fumoleau, P
    Goupil, A
    Heron, JF
    Cassin, MA
    Pruvot, I
    Soares, JA
    Chazard, M
    SEMINARS IN ONCOLOGY, 1996, 23 (05) : 48 - 54
  • [37] Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: Efficacy and adverse effects with special consideration of peripheral neurotoxicity
    Mayerhofer, K
    Bodner-Alder, B
    Bodner, K
    Leodolter, S
    Kainz, C
    ANTICANCER RESEARCH, 2000, 20 (5C) : 4047 - 4050
  • [38] Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer - A multicenter phase II trial
    Potamianou, A
    Androulakis, N
    Papakotoulas, P
    Toufexi, H
    Latoufis, C
    Kouroussis, C
    Christofilakis, C
    Xenidis, N
    Georgoulias, V
    Polyzos, A
    ONCOLOGY, 2005, 69 (04) : 348 - 353
  • [39] First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
    Sandercock, J
    Parmar, MKB
    Torri, V
    Qian, W
    BRITISH JOURNAL OF CANCER, 2002, 87 (08) : 815 - 824
  • [40] First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
    J Sandercock
    M K B Parmar
    V Torri
    W Qian
    British Journal of Cancer, 2002, 87 : 815 - 824
12345